We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$955M
AUM Growth
+$74.9M
Cap. Flow
+$18.7M
Cap. Flow %
1.96%
Top 10 Hldgs %
28.16%
Holding
94
New
8
Increased
32
Reduced
32
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.3M
2
BDX icon
Becton Dickinson
BDX
+$9.95M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.64M
4
TMO icon
Thermo Fisher Scientific
TMO
+$8.62M
5
MDT icon
Medtronic
MDT
+$8.09M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.6M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$13M
3
CI icon
Cigna
CI
+$10.1M
4
PFE icon
Pfizer
PFE
+$9.23M
5
ELV icon
Elevance Health
ELV
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 98.85%
2 Industrials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.02T
$35.1M 3.68%
97,000
+7,000
+8% +$2.22M
UNH icon
2
UnitedHealth
UNH
$376B
$30.4M 3.19%
54,800
-1,200
-2% -$631K
BSX icon
3
Boston Scientific
BSX
$69.5B
$30M 3.14%
695,000
-30,000
-4% -$1.2M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$121B
$30M 3.14%
96,000
+1,000
+1% +$288K
TMO icon
5
Thermo Fisher Scientific
TMO
$213B
$27M 2.83%
52,500
+15,400
+42% +$8.62M
HUM icon
6
Humana
HUM
$43.7B
$24.6M 2.57%
44,000
+1,000
+2% +$486K
CI icon
7
Cigna
CI
$73.7B
$24.2M 2.54%
75,000
-36,000
-32% -$10.1M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$78.5B
$24M 2.51%
32,000
+18,000
+129% +$11.3M
ABBV icon
9
AbbVie
ABBV
$443B
$21.9M 2.29%
149,626
-40,374
-21% -$5.79M
ELV icon
10
Elevance Health
ELV
$81.5B
$21.9M 2.29%
40,000
-17,000
-30% -$8.13M
MRK icon
11
Merck
MRK
$322B
$21.8M 2.28%
215,000
-50,000
-19% -$4.46M
ABMD
12
DELISTED
Abiomed Inc
ABMD
$21.7M 2.27%
85,900
+12,900
+18% +$3.48M
COR icon
13
Cencora
COR
$60.6B
$21.4M 2.24%
136,000
+11,000
+9% +$1.58M
CVS icon
14
CVS Health
CVS
$133B
$21.3M 2.23%
225,000
-65,000
-22% -$6.43M
GILD icon
15
Gilead Sciences
GILD
$162B
$21.2M 2.22%
270,000
+70,000
+35% +$4.41M
MDT icon
16
Medtronic
MDT
$109B
$21M 2.2%
240,000
+90,000
+60% +$8.09M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.6B
$20.5M 2.15%
237,000
+97,000
+69% +$8.64M
BDX icon
18
Becton Dickinson
BDX
$45.6B
$20.1M 2.1%
85,000
+40,000
+89% +$9.95M
MCK icon
19
McKesson
MCK
$100B
$19.5M 2.04%
50,000
-13,000
-21% -$4.51M
JAZZ icon
20
Jazz Pharmaceuticals
JAZZ
$15.9B
$18.9M 1.98%
131,500
-28,500
-18% -$4.33M
JNJ icon
21
Johnson & Johnson
JNJ
$618B
$17.4M 1.82%
100,000
– –
PFE icon
22
Pfizer
PFE
$143B
$16.3M 1.71%
350,000
-190,000
-35% -$9.23M
DHR icon
23
Danaher
DHR
$137B
$15.6M 1.63%
69,936
+9,024
+15% +$2.21M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$27.5B
$15.5M 1.63%
75,000
– –
AXNX
25
DELISTED
Axonics, Inc. Common Stock
AXNX
$15.4M 1.61%
210,000
-30,000
-13% -$2.07M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rhenman & Partners Asset Management held 94 positions worth $955M, up 8.5% from $880M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management's Q3 2022 filing shows 8 new, 32 increased, 32 reduced and 4 closed positions. Its largest new stake was Insulet: 29,000 shares worth $7.5M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q3 2022 buy was Insulet: 29,000 shares worth $7.5M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q3 2022, an estimated $11.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $13.6M.
  • Rhenman & Partners Asset Management fully exited Align Technology in Q3 2022, selling an estimated $4.26M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $955M portfolio in Q3 2022.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q3 2022.
  • Rhenman & Partners Asset Management's portfolio value rose 8.5% quarter-over-quarter to $955M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.